Literature DB >> 26622738

Expression and mutation analysis of Cyclin A and Ki-67 in glioma and their correlation with tumor progression.

Cheng Miao1, Zhiyong Wang2, Jing Yang3, Jing Li1, Xunzhao Gao1.   

Abstract

The present study aimed to analyze the expression and mutation of Cyclin A and Ki-67 in gliomas, and determine their correlation with tumor progression. Tissue samples of 186 diagnosed glioma patients were examined immunohistochemically for Cyclin A and Ki-67 expression. Gene mutation analysis was performed on genomic DNA extracted from patient samples, using polymerase chain reaction amplification and sequencing. Cyclin A and Ki-67 expression were observed in the glioma and lymphatic metastasis tissues, and were analyzed using SPSS 14.0 statistical software. Of the total patients, 64 (34.41%) were Cyclin A-positive and 68 (36.56%) were Ki-67-positive. The expression of Cyclin A and Ki-67 in glioma was positively correlated with lymphatic metastasis. Statistically significant differences were observed in the mutation rate of Ki-67 (P<0.05), but not Cyclin A (P>0.05), between the gliomas and metastatic tumors. In conclusion, Cyclin A and Ki-67 are highly expressed in glioma tissues, and their expression and mutation are associated with the lymphatic metastasis of glioma in the brain. It may be concluded that Cyclin A and Ki-67 may be used as biomarkers to guide the diagnosis of glioma and evaluate the prognosis of affected patients.

Entities:  

Keywords:  Cyclin A; Ki-67; glioma; lymphatic metastasis

Year:  2015        PMID: 26622738      PMCID: PMC4533753          DOI: 10.3892/ol.2015.3474

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  20 in total

1.  Contributors to contrast between glioma and brain tissue in chemical exchange saturation transfer sensitive imaging at 3 Tesla.

Authors:  Rachel Scheidegger; Eric T Wong; David C Alsop
Journal:  Neuroimage       Date:  2014-05-20       Impact factor: 6.556

2.  Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme.

Authors:  Helen Athanassiou; Maria Synodinou; Evagelos Maragoudakis; Mihalis Paraskevaidis; Cosmas Verigos; Despina Misailidou; Dosia Antonadou; George Saris; Konstantinos Beroukas; Pantelis Karageorgis
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

3.  LAP3 promotes glioma progression by regulating proliferation, migration and invasion of glioma cells.

Authors:  Xiaojuan He; Qingfeng Huang; Xiaojun Qiu; Xianchen Liu; Guan Sun; Jun Guo; Zongmei Ding; Lixiang Yang; Na Ban; Tao Tao; Dongling Wang
Journal:  Int J Biol Macromol       Date:  2014-10-24       Impact factor: 6.953

Review 4.  Predictive biomarkers in adult gliomas: the present and the future.

Authors:  Laure Thomas; Anna L Di Stefano; François Ducray
Journal:  Curr Opin Oncol       Date:  2013-11       Impact factor: 3.645

5.  Expression of proliferation markers Ki67, cyclin A, geminin and aurora-kinase A in primary breast carcinomas and corresponding distant metastases.

Authors:  Anna-Mária Tökés; A Marcell Szász; Franciska Geszti; Lilla V Lukács; István Kenessey; Eszter Turányi; Nóra Meggyesházi; István A Molnár; János Fillinger; Ibolya Soltész; Katalin Bálint; Zoltán Hanzély; Gabriella Arató; Miklós Szendröi; Janina Kulka
Journal:  J Clin Pathol       Date:  2015-01-16       Impact factor: 3.411

6.  The prognostic value of overexpression of Skp2 mRNA in non-small cell lung cancer.

Authors:  Iwao Takanami
Journal:  Oncol Rep       Date:  2005-04       Impact factor: 3.906

Review 7.  Novel biomarkers in malignant melanoma.

Authors:  Anja K Bosserhoff
Journal:  Clin Chim Acta       Date:  2006-02-09       Impact factor: 3.786

8.  Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis.

Authors:  Taka-aki Masuda; Hiroshi Inoue; Hideto Sonoda; Shinji Mine; Yasuji Yoshikawa; Keiko Nakayama; Kei-Ichi Nakayama; Masaki Mori
Journal:  Cancer Res       Date:  2002-07-01       Impact factor: 12.701

9.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

Review 10.  Temozolomide for high grade glioma.

Authors:  Michael G Hart; Robert Grant; Ruth Garside; Gabriel Rogers; Margaret Somerville; Ken Stein
Journal:  Cochrane Database Syst Rev       Date:  2008-10-08
View more
  7 in total

1.  Cyclin A in nonfunctioning pituitary adenomas.

Authors:  Elisa B Lamback; Alexandro Guterres; Monique Alvares Barbosa; Carlos Henrique de Azeredo Lima; Debora Aparecida Silva; Aline Helen da Silva Camacho; Leila Chimelli; Leandro Kasuki; Mônica R Gadelha
Journal:  Endocrine       Date:  2020-07-03       Impact factor: 3.633

2.  Overexpression of prothymosin-α in glioma is associated with tumor aggressiveness and poor prognosis.

Authors:  Anurag Kumar; Vikas Kumar; Mohit Arora; Manish Kumar; Prajwal Ammalli; Bhaskar Thakur; Jitender Prasad; Sarita Kumari; Mehar Chand Sharma; Shashank Sharad Kale; Shyam S Chauhan
Journal:  Biosci Rep       Date:  2022-04-29       Impact factor: 3.976

3.  Reciprocal Role Of DNA Methylation And Sp1 Binding In Ki-67 Gene Transcription.

Authors:  Lian-Tao Li; Xun Wang; Wen-Tao Zhu; Guo-Wei Qian; Dong-Sheng Pei; Jun-Nian Zheng
Journal:  Cancer Manag Res       Date:  2019-11-18       Impact factor: 3.989

4.  Therapeutic potential of parkin as a tumor suppressor via transcriptional control of cyclins in glioblastoma cell and animal models.

Authors:  Lila Rouland; Eric Duplan; Lígia Ramos Dos Santos; Aurore Bernardin; Karen S Katula; Guidalberto Manfioletti; Ahmed Idbaih; Frédéric Checler; Cristine Alves da Costa
Journal:  Theranostics       Date:  2021-11-01       Impact factor: 11.556

5.  Long Noncoding RNA miR210HG as a Potential Biomarker for the Diagnosis of Glioma.

Authors:  Weijie Min; Dongwei Dai; Jiaqi Wang; Dandan Zhang; Yuhui Zhang; Guosheng Han; Lei Zhang; Chao Chen; Xiulong Li; Yanan Li; Zhijian Yue
Journal:  PLoS One       Date:  2016-09-27       Impact factor: 3.240

6.  Cyclin Y Modulates the Proliferation, Invasion, and Metastasis of Hepatocellular Carcinoma Cells.

Authors:  Kaishun Shi; Qingjing Ru; Chenyi Zhang; Jie Huang
Journal:  Med Sci Monit       Date:  2018-03-20

7.  Immunohistochemical analysis of cyclin A expression in Wilms tumor.

Authors:  Sanja Radojević-Škodrić; Dimitrije Brašanac; Slaviša M Đuričić; Sofija Glumac; Zlatibor Lončar; Ivan Pavlović; Ana Todorović; Gorana Nikolić; Ivana Baralić; Snežana Pejić
Journal:  PeerJ       Date:  2019-01-11       Impact factor: 2.984

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.